10-Q · May 18, 2026
ABVC BioPharma's Q1 2026 report reveals no revenue generation, continuing a trend from previous periods, with operating expenses increasing by 127% year-over-year. The net loss grew to $1.69 million, reflecting…
Earnings analysis · 10-Q
ABVC earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, or segment results, so current-period financial trends cannot be assessed from the available text. The principal disclosure is that…
Read full summary
The provided 10-Q excerpt does not include income-statement, balance-sheet, cash-flow, or segment results, so current-period financial trends cannot be assessed from the available text. The principal disclosure is that controls remained ineffective as of June 30, 2026, with prior material misstatements and a restatement linked to an existing material weakness. Management terminated the relevant external advisor and is hiring technical accounting personnel, but remediation remains in progress and no quantitative guidance was provided.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
No prior-period impact from control deficiency
ABVC reported no material impact on prior-period financial statements from the internal-control deficiency identified during the quarter ended June 30, 2026.
-
External advisor engagement terminated
The company terminated the external advisor associated with the control deficiency during the quarter ended June 30, 2026.
-
Control remediation plan underway
ABVC is developing a remediation plan and is working to hire personnel with requisite technical accounting knowledge as of August 12, 2026.
-
No material legal proceedings
The company reported no material legal proceedings as of August 12, 2026.
-
January equity financing completed
ABVC issued 131,280 common shares for aggregate proceeds of $256,000 on January 12, 2026, at $1.95 per share.
What to watch
-
Material weakness and restatement
Disclosure controls were ineffective as of June 30, 2026 because of a material weakness previously described in the 2025 Form 10-K; the weakness resulted in material misstatements and a restatement.
-
Ongoing reporting and market risk
The company stated that failure to remediate the material weakness, or identification of additional weaknesses, could adversely affect its reporting and financial obligations, financial condition, and common-stock trading price.
-
External-advisor oversight deficiency
During the quarter ended June 30, 2026, ABVC identified inadequate controls over due diligence and monitoring of external advisors, including failure to timely identify regulatory or disciplinary matters.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook and does not provide operating guidance.
Earlier filings 4
10-K · March 3, 2026
ABVC is an early-stage biotech with a pipeline of seven drug candidates and one medical device, generating revenue primarily from out‑licensing IP and CDMO services. The company reported continued clinical progress…
10-Q · May 17, 2024
ABVC reported Q1 revenue of $1,205 and a net loss of $3,981,019 (EPS $(0.40)), driven by sharply lower revenue versus prior year and large non-cash stock-based compensation. The company ended the quarter with $30,489 in…
10-Q · August 14, 2023
ABVC reported a sharp revenue collapse to $6,109 for the quarter ended June 30, 2023 (Q2) versus $312,860 in Q2 2022 and posted net loss of $2,315,225 (net loss per share $(0.68)), worsening vs prior-year quarter.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.